Cargando…
Cell‐based therapies for the treatment of rheumatoid arthritis
Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664399/ https://www.ncbi.nlm.nih.gov/pubmed/38018576 http://dx.doi.org/10.1002/iid3.1091 |
_version_ | 1785148729752289280 |
---|---|
author | Moghaddam, Maryam Zare Mousavi, Mohammad Javad Ghotloo, Somayeh |
author_facet | Moghaddam, Maryam Zare Mousavi, Mohammad Javad Ghotloo, Somayeh |
author_sort | Moghaddam, Maryam Zare |
collection | PubMed |
description | Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and none‐stem cells has been increasingly considered as a therapeutic option in various diseases. This is partly due to the unique properties of stem cells that divide and differentiate from the specialized cells in the damaged tissue. Moreover, stem cells and none‐stem cells, impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present review, the efficacy of cell‐based therapy with four main types of stem cells, including mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and human amniotic membrane cells, as well as none‐stem cells, including regulatory T cells, chimeric antigen receptor T cells, and tolerogenic dendritic cells will be evaluated. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell and none‐stem cell origin, conditioning regimen, limitations, and complications will be discussed. |
format | Online Article Text |
id | pubmed-10664399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106643992023-11-22 Cell‐based therapies for the treatment of rheumatoid arthritis Moghaddam, Maryam Zare Mousavi, Mohammad Javad Ghotloo, Somayeh Immun Inflamm Dis Review Article Autoimmune diseases, including rheumatoid arthritis that is the most prevalent rheumatic autoimmune disorder, affect autologous connective tissues caused by the breakdown of the self‐tolerance mechanisms of the immune system. During the last two decades, cell‐based therapy, including stem cells and none‐stem cells has been increasingly considered as a therapeutic option in various diseases. This is partly due to the unique properties of stem cells that divide and differentiate from the specialized cells in the damaged tissue. Moreover, stem cells and none‐stem cells, impose immunomodulatory properties affecting the diseases caused by immunological abnormalities such as rheumatic autoimmune disorders. In the present review, the efficacy of cell‐based therapy with four main types of stem cells, including mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, and human amniotic membrane cells, as well as none‐stem cells, including regulatory T cells, chimeric antigen receptor T cells, and tolerogenic dendritic cells will be evaluated. Moreover, other related issues, including safety, changes in immunological parameters, suitable choice of stem cell and none‐stem cell origin, conditioning regimen, limitations, and complications will be discussed. John Wiley and Sons Inc. 2023-11-22 /pmc/articles/PMC10664399/ /pubmed/38018576 http://dx.doi.org/10.1002/iid3.1091 Text en © 2023 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Moghaddam, Maryam Zare Mousavi, Mohammad Javad Ghotloo, Somayeh Cell‐based therapies for the treatment of rheumatoid arthritis |
title | Cell‐based therapies for the treatment of rheumatoid arthritis |
title_full | Cell‐based therapies for the treatment of rheumatoid arthritis |
title_fullStr | Cell‐based therapies for the treatment of rheumatoid arthritis |
title_full_unstemmed | Cell‐based therapies for the treatment of rheumatoid arthritis |
title_short | Cell‐based therapies for the treatment of rheumatoid arthritis |
title_sort | cell‐based therapies for the treatment of rheumatoid arthritis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664399/ https://www.ncbi.nlm.nih.gov/pubmed/38018576 http://dx.doi.org/10.1002/iid3.1091 |
work_keys_str_mv | AT moghaddammaryamzare cellbasedtherapiesforthetreatmentofrheumatoidarthritis AT mousavimohammadjavad cellbasedtherapiesforthetreatmentofrheumatoidarthritis AT ghotloosomayeh cellbasedtherapiesforthetreatmentofrheumatoidarthritis |